From Yahoo Finance: 2025-05-07 13:28:00

Jim Cramer revisits his love for the Magnificent 7 stocks on CNBC’s Squawk on the Street, noting their performance in tough times. He sarcastically questions Trump’s blame of Biden for economic woes. The discussion shifts to Elon Musk and DOGE, with Cramer wondering about Musk’s focus. US weekly jobless claims surge to 241,000, attributed to Trump administration layoffs.

Cramer highlights the importance of ethane in US-China trade relations. The article lists stocks Cramer mentioned on CNBC. Becton, Dickinson and Company (NYSE:BDX) sees a 25% YTD drop due to profit guidance cuts. Cramer expresses shock at BDX’s poor performance and discusses potential investment opportunities in AI stocks. BDX ranks 3rd on Cramer’s list of discussed stocks.

BDX, a healthcare firm, faces challenges with tariff constraints impacting profit guidance. Cramer expresses disappointment in BDX’s recent performance, emphasizing the company’s significant decline. Despite recognizing BDX’s potential, Cramer believes other AI stocks may offer better returns in a shorter timeframe. Check out a report on a promising AI stock trading at less than 5 times its earnings for more information. 1. The US economy added 943,000 jobs in July, surpassing expectations and indicating a strong recovery from the pandemic. The unemployment rate dropped to 5.4%, the lowest since March 2020. This growth was mainly driven by gains in leisure and hospitality sectors.

2. In the ongoing Tokyo Olympics, the United States leads the medal count with 41 total medals, including 14 golds. China follows closely behind with 40 total medals, 19 of which are gold. Athletes from both countries have been performing exceptionally well across various sports.

3. The CDC has revised its mask guidelines, recommending that fully vaccinated individuals wear masks indoors in areas with high COVID-19 transmission rates. This decision comes as the Delta variant continues to spread rapidly across the country, causing a surge in cases and hospitalizations.



Read more at Yahoo Finance: “A Shocking Miss for This Once-Reliable Med Tech Giant”